Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at its Visp, Switzerland, plant. The expansion, which should go live in 2028, will add two multipurpose 1,200L manufacturing suites and related infrastructure to supply antibody-drug conjugates. The suites will take up some 2,000 square meters and double the company’s capacity, plus create 200 new jobs. Source: Fierce Pharma 12/11/2024